Given the in vitro and in vivo evidence indicating the potential therapeutic implications of CTLA-4 targeting in MS, several clinical trials have been launched to evaluate them in the clinical setting (Table 2). The gene discussed is CTLA4; the disease is myeloid sarcoma.